number of access : ?
number of downloads : ?
ID 116086
Author
Bando, Hiroshi Tokushima University|Japan Low Carbohydrate Diet Promotion Association|Sakamoto Hospital KAKEN Search Researchers
Sakamoto, Kazuki Sakamoto Hospital
Ogawa, Tomoya Sakamoto Hospital
Kondo, Naoki Sakamoto Hospital
Hatakeyama, Shigeki Sakamoto Hospital
Kobayashi, Toshiharu Sakamoto Hospital
Iwatsuki, Noboru Sakamoto Hospital
Keywords
Insulin Degludec and Liraglutide (IDegLira)
glucagon-like peptide 1 (GLP-1)
DUAL (Dual Action of Liraglutide and Insulin Degludec)
European Xultophy Treatment Retrospective Audit (EXTRA)
Japan LCD Promotion Association (JLCDPA)
Content Type
Journal Article
Description
Two patients with Type 2 Diabetes Mellitus (T2DM) were treated with Xultophy. Xultophy consists of degludec and liraglutide (IDegLira). It is the combination of long-acting insulin and Glucagon like Peptide-1 Receptor Agonist (GLP-1RA) and is characteristic for effective agent for improving glucose variability for patients with T2DM. However, clinical responses are not always satisfactory due to different complication and background of each patient. We have experienced two impressive T2DM cases. Case 1 was 59-year-old male with hypertension for 20 years and T2DM for 3 years. He was treated on Novolin 30R 30/21 units twice a day, and after that Xultophy 32 doses brought him successful glucose profile. Case 2 was 78-year-old male with hypertension, bronchial asthma, hyperuricemia, and others with heavy alcohol drinking for 50 years. He was formerly treated by Insulin detemir, Liraglutide, exenatide and Degludec/NovoRapid, but has been recently unstable in glucose control. Xultophy up to 40 doses could not successfully improve glucose variability. One of the less responsiveness to Xultophy would be due to impaired liver function. Clinical progress of both cases associated with several perspectives from various points of view are discussed in this article.
Journal Title
Edelweiss Applied Science and Technology
ISSN
25768484
Publisher
Edelweiss Publications
Volume
5
Issue
1
Start Page
21
End Page
24
Published Date
2021-03-29
Rights
This is an open-access article distributed under the terms of the Creative Commons Attribution License(https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
DOI (Published Version)
URL ( Publisher's Version )
FullText File
language
eng
TextVersion
Publisher
departments
Medical Sciences